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Abstract 15 
 16 
The disclosure of incidental findings, also called unsolicited findings, unexpected results, and 17 
secondary variants, is increasingly recognised as an issue in clinical and research genetics 18 
contexts. The rise of next generation sequencing methods has only intensified the issue, 19 
increasing the likelihood of incidental findings appearing. This review focuses on empirical 20 
research on the ethical issues involved. Electronic databases were searched for articles 21 
covering quantitative and qualitative research on the ethical issues involved in the disclosure 22 
of incidental findings in clinical and research genetics contexts. 16 articles were ultimately 23 
accepted for review. Data was extracted and synthesised on the factors that should be taken 24 
into account during the decision-making process surrounding the disclosure of an incidental 25 
finding in a genetics context. These factors include the possibility of disclosure, various 26 
practical and technical factors, and various ethical factors.  We suggest the development of a 27 
decision-making tree, involving an exploration of the practical and ethical concerns raised by 28 
the studies. This is in our view the best way of handling the wide variety of both possible 29 
incidental findings and parties interested in the disclosure of incidental findings. 30 
 31 
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 39 
Introduction 40 
Incidental findings (IFs) have been defined in research contexts as findings having 41 
potential health or reproductive importance for an individual research participant, discovered 42 
in the course of conducting research but beyond the aims of the study. [1] The term itself is 43 
somewhat contested. [2] Some authors prefer alternative terms such as unsought for findings, 44 
unsolicited findings, and off-target results. [3-5] They have been reported most frequently in 45 
neuroimaging, oncology and genetics contexts. [1] However, despite a multitude of case 46 
reports, opinion pieces and general articles attesting to the widespread and frequent 47 
appearance of IFs in all sorts of research and clinical contexts, there is very little public 48 
guidance available at a government, professional or academic level, and what is available is 49 
inconsistent. [6-8] There have been several systematic reviews published in recent years on 50 
IFs arising in imaging contexts. [9-11] However, the focus of these systematic reviews is 51 
generally the frequency of IFs; how to handle IFs, and ethical explorations or justifications of 52 
particular ways of handling IFs, are touched upon in the discussion section of each article but 53 
are not the aim of any of the reviews. 54 
It is unclear whether IFs can be said to exist in clinical contexts, because it can be 55 
argued that all results, whether beyond the aims of the study or not, are actually included in 56 
the aim of clinical care and are thus not “incidental”. [12, 13] Nonetheless, making a 57 
distinction between what is the target of a clinical test or procedure and what is more “off-58 
target” can be useful when developing consent procedures that sufficiently inform patients 59 
and/or guardians about both types of results, [4] as well as useful when devising follow-up 60 
procedures and formulating professional obligations. Similarly, it is helpful in research 61 
contexts to make a distinction between research results and IFs, because there are key 62 
differences between the two, related to whether the finding falls inside or outside the domain 63 
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or expertise of the researcher, and whether the obligations for the researcher are clear or 64 
ambiguous. [13] The present review involved a search for literature on what are commonly 65 
accepted to be IFs: findings that fall outside the aim of the study, and/or are unanticipated, 66 
and/or are not the specific focus or target of the particular research or clinical query.  67 
In a previous article, we performed a systematic literature review of the ethical reasons 68 
presented in the argument-based literature for and against the disclosure of IFs arising in 69 
clinical and research genetics contexts. [2] The present review also focuses on the disclosure 70 
of IFs arising in genetics settings, but this time based on the empirical research that has been 71 
done thus far. As next generation sequencing technologies move from research to clinical 72 
contexts and become increasingly widespread, the huge amounts of data of widely varying 73 
significance that they produce make IFs a growing issue. [14-16] We continue to use the term 74 
“incidental findings” because it is the keyword most commonly used to describe the 75 
phenomenon, although we do have reservations about this term. [17] 76 
 77 
 78 
Methods 79 
 80 
Search methods 81 
Articles were sought that fulfilled four criteria: empirical research, in research or 82 
clinical genetics settings, ethically focused, and related to the disclosure of IFs. Various 83 
keywords were entered in several electronic databases for each of the four categories (Figure 84 
1). Articles published before 2001, the year in which the initial sequencing and analysis of the 85 
human genome was completed, were excluded, as the completion of the human genome 86 
project marked a crucial turning-point in the practice of genetics. [18] The Pubmed searches 87 
were saved and weekly electronic updates requested until June 2013. 88 
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Articles were excluded if IFs or similar concepts were mentioned only in passing, only 89 
research results were considered, there was no empirical research conducted, or there was no 90 
reflection on ethical issues. By the latter we understand explicit treatment of established 91 
ethical principles and concepts, [19, 20] or reflection on the values and attitudes motivating 92 
actions and opinions. [21] Articles on screening, biobanking and direct-to-consumer genetic 93 
testing were also excluded, as these raise additional public policy and social issues, and have 94 
been covered in several recent reviews. [22-24] Finally, the references of all the articles 95 
included up to this point for review were scanned, and citation searches were run on all the 96 
included articles in Web of Science. 97 
 98 
Data extraction and synthesis 99 
The resulting articles utilised a range of quantitative and qualitative methods, covering a 100 
range of clinical and research genetics contexts and targeting a number of different publics. 101 
Due to this considerable heterogeneity, it was inappropriate to pool the data in a meta-102 
analysis. The data are instead presented in summary form (Table 1). A quality appraisal of the 103 
articles was conducted using the quality assessment tool (Qual Syst) developed by Kmet et al. 104 
(Supplementary Tables S1 and S2). [25] Given the relatively limited number of articles 105 
eligible for review, the cut-off point chosen for article inclusion was what Kmet et al. 106 
designate as the relatively liberal quality score of 55%.  A thematic analysis of the articles 107 
revealed that the single issue running through all articles was the factors relevant during the 108 
decision-making process surrounding the disclosure of an IF. Data extraction was 109 
subsequently conducted to identify these factors.  110 
 111 
 112 
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Results 113 
The electronic database searches resulted in 126 possible articles for review (excluding 114 
duplicates; Figure 1). There were 16 articles ultimately accepted for review. [26-41] 115 
Snowballing resulted in no additional articles. A high proportion of articles were included that 116 
were published in the last two years, [26-29, 31-35, 39-41]confirming the relevancy of the 117 
topic. 118 
A range of characteristics of the reviewed articles are listed in Table 1, for 119 
comparison. All received a quality score of more than 55% (Supplementary Tables S1 and 120 
S2), and thus were included for subsequent review.  Our analysis disregards the fundamental 121 
methodological differences between quantitative and qualitative research, as well as the 122 
specific research question of each article, in favour of an extraction and synthesis of themes. It 123 
was not the intention of the current paper to determine what the most important or most cited 124 
themes are. 125 
Thematic analysis led to the discovery of a single issue recurring in all articles: what 126 
factors should be taken into account in genetics contexts during the decision-making process 127 
surrounding the disclosure of an IF? We have taken this issue to structure the data extraction 128 
and synthesis of this review. The study-specific results, related to which precise factors such 129 
as gender or lifestyle influence disclosure preferences and decisions, have little or no value in 130 
guiding clinical or research practice, and are not dealt with here. 131 
 132 
The possibility of disclosure 133 
The first important factor to be taken into account during the decision-making process 134 
is whether disclosure is in fact a possibility. That is, are the medical professionals (be they 135 
clinicians or researchers) and the potential recipients of the IF open to the possibility of 136 
disclosure, or have they already indicated that disclosure is not an option? [26, 35, 38, 39] The 137 
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reviewed articles dealing with medical professionals indicate a general consensus that 138 
clinically significant IFs should be returned. [26, 28, 29, 33-35, 37, 40, 41] This in many ways 139 
matches the reported general desire of non-professionals to receive clinically significant IFs. 140 
[28, 30, 32, 36, 40] However, the potential presence of a sizeable minority wishing to exert 141 
their right not to know, alongside the varying impact of certain demographic and health 142 
factors on disclosure preferences, indicate the need for a thorough procedure to determine 143 
potential recipients’ wishes. [36] Such pre-test discussions are useful to avoid “surprises”, 144 
incorporate patients and parents in decision-making, and make it clear to patients if geneticists 145 
have intentionally limited the possibility of IFs. [28, 40] Consent forms should be specific 146 
enough to help when later making a disclosure decision, according to genetics researchers, 147 
[33] while also leaving room for the possibility of participant disclosure preferences changing 148 
over time, according to IRB chairs. [39] 149 
 150 
Practical and technical factors 151 
Another group of factors cited in the reviewed articles as relevant in the decision-152 
making process are practical and technical factors. This group of factors can be further 153 
divided into three subgroups. A first subgroup involves questions around the clinical utility of 154 
the finding, including the seriousness, urgency, treatability (dependent also on cost, impact 155 
and availability), impact on the quality of life, probability and disease context of the finding. 156 
[26, 28-30, 32-38, 40, 41] A second subgroup involves scientific factors: whether the finding 157 
has been replicated and by an independent research group; the robustness and quality of the 158 
finding (e.g. whether the finding comes from a known coding region); how expected or 159 
“incidental” the finding is; and the extent and complexity of the information provided by the 160 
IF. [27-29, 33, 35, 37-40] A third subgroup involves communication factors: who should 161 
disclose and to whom; the capacity of the team to handle complex and uncertain data, explain 162 
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the IF sensitively and comprehensively, and provide medical advice; the capacity of the 163 
patient or research participant to understand the finding; complex family dynamics, including 164 
how to respect the growing maturity of children; and the possibility or necessity to consult 165 
colleagues and the institutional review board about the finding. [26-28, 31-33, 37, 40] 166 
 167 
Ethical factors 168 
A final group of relevant factors dealt with in the reviewed literature are ethical 169 
factors. By this we understand established ethical principles and concepts, [19, 20] as well as 170 
the values and attitudes motivating actions and opinions. [21] This group of ethical factors can 171 
be further categorised into subgroups. It should be noted that several of the subgroups 172 
overlap. 173 
Several articles mention the ideals of maximising benefits and minimising harms. [26, 174 
27, 32, 37, 40] Beneficence and non-maleficence were cited by genetic researchers in one 175 
interview study as motivations for both the disclosure and non-disclosure of IFs. [37] The 176 
specific harms of disclosing IFs mentioned in the reviewed literature include possible risks to 177 
privacy and confidentiality, insurance and employment discrimination, and various 178 
psychological harms such as fear, anxiety and confusion. [26, 27, 31, 32, 40] There was also 179 
the concern on the part of researchers that research participants may not have the support or 180 
resources necessary to understand the risks of IFs and take appropriate follow-up steps. [37] It 181 
is noteworthy that while the lay people in one study responded to the possibility of harms 182 
stemming from IFs by starting to speak about their autonomy, health care professionals in the 183 
same study responded by continuing to speak in terms of beneficence and non-maleficence. 184 
[40] 185 
Respect for autonomy and choice is an additional relevant ethical factor, though 186 
sometimes contentious. [26, 27, 35, 37, 39, 40] The lay groups in a focus group study on 187 
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clinical whole genome sequencing (WGS) spoke of the ideal of autonomous decision-making, 188 
and considered respect for autonomy and choice to be the basis for disclosure, not the clinical 189 
relevance of the IF as decided by a professional. [40] Some IRB chairs involved in an 190 
interview study argued that respect for the autonomy of research participants is a higher value 191 
than beneficence, distinguishing between research and clinical care. [39] In their view, the 192 
informed consent process presents the perfect opportunity to respect potential participants’ 193 
autonomy. In contrast, some clinical genetics professionals surveyed set actionability and 194 
definite beneficence above patient choice. [35] Similarly, some genetic specialists in an 195 
interview study reported that they would find it very difficult if patients had opted out of 196 
disclosure and an IF was discovered with known clinical significance. [27] Some IRB chairs 197 
in a related interview study stated that they would give more weight to a medical opinion 198 
favouring disclosure or nondisclosure on grounds of the participant’s beneficence than the 199 
participant’s own preferences. [41] One IRB chair involved in another interview study 200 
conducted by the same group spoke not just of the recipient’s right to know and respect for 201 
their autonomy but of their “need to know” in certain life-threatening or life-changing cases. 202 
[26] Some researchers in another interview study were also of the opinion that participants 203 
should have access to clinically relevant information and the choice to learn this information; 204 
the authors of the study note that the “right not to know” was not always acknowledged by 205 
interviewees. [37] 206 
The principle of justice featured in focus group discussions with health care 207 
professionals and lay people on the equitable use of limited resources. [40] Moreover, the 208 
ideas of property and ownership in terms of IFs specifically or the genetic sequence as a 209 
whole fall under the concept of justice, as well as being related to respect for individual 210 
autonomy. [40] At the same time, it was acknowledged that the inherited nature of genetic 211 
information complicates questions of ownership.  212 
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The theme of duties and responsibilities is a further subdivision of ethical factors 213 
relevant in the decision-making process. [26, 31, 32, 37, 40, 41] Medical genetic specialists, 214 
genomic researchers, and IRB chairs involved in an interview study spoke of their obligation 215 
to respect the wishes of the participant or patient to receive an IF. [26] Primary care 216 
professionals in focus groups spoke of their duty to disclose IFs, especially when treatable 217 
conditions were involved, while geneticists in the same study were more hesitant when 218 
applying the specific term “duty” to themselves. [31] Lay people in a related study agreed that 219 
health care professionals have an obligation to disclose IFs. [32] Some researchers spoke of 220 
the responsibility that they feel towards those participating in their research projects. [37] 221 
Some set this against the context of research, and said they feel a certain sense of 222 
responsibility because of the trust that participants commit to the researchers and their 223 
expertise; others simply set it against the context of the normal give-and-take of human 224 
relationships. The need to balance the duties of researchers to individual participants and 225 
society was acknowledged. [37] Some genomic researchers involved in an interview study 226 
stressed the purpose of research, to generate knowledge, as a reason not to disclose IFs. [41] 227 
Mention was also made in one reviewed study of the responsibility that patients have, 228 
especially in terms of keeping up with new implications of their genetic data due to advances 229 
in genetic knowledge. [40] Health care professionals in this study related the idea of patient 230 
responsibility with the practical challenges facing professionals, while for the lay participants 231 
it was more an idea of mutual patient-clinician responsibility, linked to the idea of patient 232 
choice.  233 
Finally, the presence of a minor has an impact on the decision-making process. [28, 234 
29, 34, 35, 40] Two surveys of clinical genetics specialists uncovered increased reluctance to 235 
disclose IFs when minors were involved compared to the situation involving adults. [29, 35] 236 
This reluctance was shared by professional stakeholders involved in an interview and focus 237 
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group study on paediatric genomic research and clinical practice, and was especially related to 238 
IFs involving reduced penetrance, variable expressivity, delayed onset, or the absence of any 239 
available treatment. [28] In contrast, public stakeholders involved in the same study were 240 
willing to accept any ambiguity surrounding IFs as simply part of the ambiguousness of life. 241 
Their desire to receive IF information was motivated by a wish to be prepared. It was their 242 
view that parents should decide if, when and how IFs are shared with their children, although 243 
medical professionals should act as a backup to ensure that children do receive certain types 244 
of IFs once they reach a certain age. [28] A survey of clinical genetics professionals revealed 245 
that the presence of a minor had a variable influence on the decision-making process, 246 
depending on the actionability and the time of onset of the IF. [34] Focus groups involving 247 
health care professionals and lay people related the presence of a minor to broader issues of 248 
inheritance and ownership of genetic information. [40] 249 
 250 
 251 
Discussion 252 
Any attempts to pull together the results of the reviewed studies need to be done 253 
carefully, because of both the high degree of heterogeneity in terms of study aims and target 254 
populations and the relatively limited number of studies that have been published to date. An 255 
additional challenge encountered while conducting this review is that while a range of search 256 
terms in a number of electronic databases were trialled, complemented by the snowballing 257 
method, there is no guarantee that all relevant literature was identified simply because of the 258 
heterogeneity of terms and keywords used in empirical bioethics publications. [42] We 259 
nonetheless consider this review to be an important exercise in order to gain an overview of 260 
the empirical ethical research that has been conducted up until now on the disclosure of IFs. 261 
Given what some anticipate as a huge increase in expected IFs as whole exome and genome 262 
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sequencing methods make the transition from research to clinical contexts, [14, 43] an 263 
overview of the issue is urgently needed. In addition, the fact that 75% of the articles 264 
reviewed in the present paper have been published in the last two years emphasises that there 265 
is currently a large amount of empirical research being done on this topic.  266 
 As already stated, the general view of medical professionals that clinically significant 267 
IFs be returned, [26, 28, 29, 33-35, 37, 40, 41] in many ways matches the general desire of 268 
non-professionals to receive clinically significant IFs. [28, 30, 32, 36, 40] The study-specific 269 
results, related to which precise factors influence disclosure preferences and decisions, have 270 
little or no value in guiding clinical practice, and have been largely disregarded in the present 271 
review. However, this is not intended to be the take-home message of the studies. Their point 272 
is more that we should be aware of the gap that exists between agreeing in general to a policy 273 
of disclosure and the specifics of each IF. These specifics include the specific context of the 274 
IF itself (including its clinical validity and utility, whether it is serious or not, how far it lies 275 
from the original aim of the genetic test), the context of the medical professional making the 276 
discovery (including their particular medical field, their ethical culture, their professional 277 
support network), and the context of the subject in whom the IF is discovered (including 278 
whether a minor is involved). With respect to the specific context of the IF itself, the 279 
development of categories of IFs accompanied by recommendations for how to deal with each 280 
category is urgently needed. Such discussions have already begun. [43, 44] This is a first step 281 
in answering the call of several of the studies for clear guidance on the disclosure of IFs. [27, 282 
29, 31, 37, 40] However, with respect to the people involved in the IF – the patient or research 283 
participant whose IF it is and the person who has made the finding – it is not categories or 284 
checklists that will help but counselling and other forms of dialogue. This issue was raised in 285 
some of the reviewed articles, which advocate a thorough pre-test discussion between medical 286 
professional and subject, [31, 32, 35, 36, 39, 40] and the need for more educational resources. 287 
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[31, 37] The discrepancy between a given IF on the one hand and the subject’s reasons for 288 
desiring disclosure and the context in which disclosure will occur on the other hand is starkly 289 
apparent in recent literature on why genetic testing for BRCA and Huntington’s mutations is 290 
pursued. [45, 46] We suggest that a sort of “decision-making tree” may be a useful and user-291 
friendly tool in coping with disclosure decisions in the clinic and research.  292 
A decision-making tree would need to start by separating technical or practical 293 
concerns and ethical concerns, [47] as we have done in structuring the results of the reviewed 294 
literature. The initial question of whether disclosure is an option or not can be incorporated 295 
into the group of practical and technical concerns. Green et al. make a distinction in the 296 
discussion of their study results between clinical judgments regarding the clinical validity or 297 
utility of the IF and ethical judgments based on whether adults or minors are involved. [29] At 298 
the beginning of a new field it is prudent to begin by exploring the extent of pragmatic 299 
concerns and clinical judgments that are possible. However, it is time to move on in the 300 
context of IFs arising in clinical and research genetics. For instance, it has now been well 301 
established that new genetic sequencing techniques such as WGS raise ethical issues because 302 
of the huge complexity and ambiguity of the data generated, [14] and this was confirmed as a 303 
concern in several of the studies reviewed above. [28, 31, 33, 37, 39, 40] Now is the time to 304 
move on to reflections about why exactly this raises ethical issues; for example, how exactly 305 
does complex and ambiguous information challenge the abilities of medical professionals to 306 
maximise benefits and minimise harms (thus furthering beneficence and maleficence), or 307 
challenge the abilities of the subjects of genetic tests to act autonomously?  308 
We envisage a decision-making tree with two major branches, one for technical or 309 
pragmatic concerns and the other for ethical concerns (Figure 2). The technical factors should 310 
be dealt with first when deciding to disclose an IF, because it can be argued that they form the 311 
basis of being able to address ethical factors such as maximising benefits and minimising 312 
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harms. In other words, it makes little sense to reflect on the ethical factors at play in the 313 
disclosure of a particular IF if the very clinical utility and validity of the finding are in doubt 314 
and the communication process will be problematic. 315 
Figure 2 thus sets technical factors before ethical factors in the decision-making 316 
process. We have arranged the three types of technical factors that came out of the reviewed 317 
literature according to what to us appears a logical order: clinical utility, scientific factors, and 318 
communication factors. A ranking of ethical values was apparent in some of the studies when 319 
considering the relative value of respect for autonomy. [35, 39, 40] Thorough ethical 320 
reflection is needed to consider how to rank ethical concepts and even whether ranking is an 321 
ethically sound idea. Given that ethical concepts are necessarily lived out in particular cultural 322 
and professional contexts, as Green et al., among others, illustrate, [29] it may prove difficult 323 
to devise a ranking of concepts that can be universally applied. The implementation of a 324 
decision-making tree may help avoid an a priori ranking of ethical concepts, by allowing 325 
different concepts to take on different weights depending on the specific context. What is 326 
certain is the importance of considering multiple factors in any single decision-making 327 
process. [26] 328 
Figure 2 is not yet a “decision-making tree” as it does not include any decisions, as 329 
such. It is a schematic representation based on the results of the present review of the factors 330 
that would need to be considered when disclosing an IF in genetics contexts. The branches 331 
and twigs on the current schematic can be added to in more detail based on the more thorough 332 
results listed above. There is room to add to the tree on the basis of other reviews. [2, 48] Our 333 
intention is not that such a tree be used by individual researchers or clinicians, but that it be a 334 
tool for use in team discussions on the disclosure of IFs. The importance of team discussions 335 
was highlighted in several of the reviewed articles. [29, 33, 37] 336 
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An example will help to illustrate how such a decision-making schematic might be 337 
used. Imagine that a clinical geneticist incidentally discovers a mutant BRCA1 gene during 338 
WGS involving a four year old girl. Following the first branch of the tree, the geneticist and 339 
their team should first consider the clinical utility of this IF and various scientific and 340 
communication factors. This is a serious IF, related to breast and ovarian cancer. A carrier of 341 
a BRCA1 mutation has an average risk by age 70 years for breast cancer of 65% and for 342 
ovarian cancer of 39%.[49] The information is currently not very urgent for the four year old 343 
girl, but it will be of later personal importance. It could be very relevant information now for 344 
the girl’s mother, aunts and grandmothers. In terms of treatability, there are early screening 345 
and prevention options, such as prophylactic mastectomy. The disease context is cancer, and 346 
it may also be relevant to consider the initial reason for carrying out WGS (the 347 
“intentionality” of the finding) and whether there is a family history of breast or ovarian 348 
cancer. Various scientific factors should be checked, such as the replication, robustness, 349 
quality, and extent of the finding, as should the communication factors listed in the results 350 
section above such as who should be the recipient of this IF.  351 
Moving to the second branch of the decision-making schematic, the following 352 
reflections come to the surface. In terms of maximising benefits, early screening resulting 353 
from the disclosure of this IF can lead to early detection, and prophylactic surgery can remove 354 
the risk almost completely. This should be weighed against minimising the possible harms of 355 
unnecessary anxiety for the child, possible over-treatment, and stigmatisation. In the context 356 
of justice, it can be asked whether it is just to devote resources to the validation, 357 
communication, and follow-up of this particular IF instead of to other health issues. It is also 358 
unclear who exactly the “owner” of this IF is, the little girl herself or maybe all her female 359 
relations (giving them the chance to also get tested). When a child is involved, it is not always 360 
obvious whose autonomous choice should be respected: that of the child, now, or of the child 361 
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once she reaches majority, or of the parents, her legal guardians, who can then choose how 362 
they want to handle the IF. Duty and responsibility issues include balancing the provision of 363 
clinical care to the family against a just distribution of finite resources. They also involve 364 
asking questions like: who is the clinical geneticist responsible for in this case? The child, the 365 
child and her immediate family, or the broader family too? Reversing the question means 366 
considering how the parents can best fulfil their responsibilities as parents and family 367 
members in this case. Is it possible that they could learn of this IF through other means, thus 368 
respecting the right of their child not to know? Finally, the age and possibly the gender of the 369 
child is a factor; additional questions would be raised if she were 14 years old, or a 17 year 370 
old boy.  371 
The problem of IFs has been identified as “one of the greatest impediments” to the 372 
immediate introduction of whole genome and exome sequencing in clinical medicine. [29] 373 
Given that medical professionals are generally in favour of disclosing clinically relevant IFs, 374 
and patients and research participants are generally in favour of receiving clinically relevant 375 
IFs, efforts should now be spent on ironing out the details, investigating when exceptions may 376 
arise and what to do when they do arise.  377 
 378 
379 
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Figure titles and legends 390 
 391 
Figure 1: Results of the electronic database searches. The search string used was: 392 
(qualitative research OR cross-sectional studies OR questionnaires OR health surveys OR 393 
cohort studies OR focus groups OR peer review) AND genetics AND ethics AND (incidental 394 
findings OR truth disclosure OR disclosure) 395 
 396 
Figure 2: Decision-making schematic for use in the disclosure of an incidental finding in 397 
genetics contexts. This tree is based on the results of the present review, and is intended for 398 
use in team discussions on the disclosure of incidental findings. The following factors should 399 
be considered when coming to a decision about disclosing a particular incidental finding: 1) 400 
Technical factors: a) clinical utility: seriousness; urgency; treatability; impact on quality of 401 
life; probability; disease context; b) scientific factors: the replication, robustness and quality, 402 
intentionality, and extent and complexity of the incidental finding; c) communication factors: 403 
who should disclose and to whom, communication capacity of the team, comprehension 404 
capacity of the recipients, family dynamics; possible/necessary consultation of 405 
colleagues/IRB. 2) Ethical factors: a) maximise benefits; b) minimise harms; c) justice issues: 406 
just distribution/utilisation, and property, ownership, and inheritance issues; d) respect for 407 
autonomy; e) duties/responsibilities: towards individuals and society, and from the viewpoint 408 
of the medical professional and the recipient; f) presence of minors.  409 
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Tables 410 
 411 
Table 1: Summary of a range of the characteristics of the 16 reviewed articles. The final column lists the factors mentioned by each article relevant in the 412 
decision-making process surrounding the disclosure of an incidental finding (IF). 413 
Author/s 
(Year) 
Country & 
setting 
Study 
population Aim Research design 
Sample size and 
response rate (RR) Summary 
Factors relevant to incidental 
findings decision-making 
Brandt, 
Shinkunas, 
Hillis, Daack-
Hirsch, 
Driessnack, 
Downing, Liu, 
Shah, Williams, 
Simon (2013) 
USA; medical 
genetics 
professionals 
(medical 
genetic 
specialists, 
genomic 
researchers, IRB 
chairs) 
to examine how a 
range of 
professionals 
perceive the relative 
importance of 
recommended 
criteria when 
applied to 
genetic/genomic IFs 
qualitative - 
telephone 
interviews 
103 professionals  
obtained through 
stratified purposive 
sampling (RR n/a) 
professionals' perspectives on 
nine selected criteria proposed 
in the literature regarding the 
importance of IF disclosure 
the IF points to a life-
threatening condition (and this 
may influence responses to 
other criteria);  individuals 
indicate in writing they wanted 
to be informed of IFs; there is a 
treatment (dependent on cost, 
impact and availability); quality 
of life will most probably be 
affected. Discussion around 
disclosing an IF regarding a 
reproductive risk for the 
individual's offspring. Less 
important criteria: analytic 
validity, high penetrance, 
association with early onset and 
relative risk more than 2.0. Also: 
do a risk-benefit assessment; 
consider the nature of the IF; 
consider the unique recipient of 
the IF 
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Downing, 
Williams, 
Daack-Hirsch, 
Driessnack, 
Simon (2013) 
USA; clinical 
genetics 
genetics 
specialists 
(medical 
geneticists, 
laboratory 
professionals, 
genetic 
counsellors, 
genetics nurses) 
to examine the 
perspectives of 
clinical genetics 
specialists regarding 
the management of 
IFs 
qualitative - 
telephone 
interviews 
50 genetics 
specialists obtained 
through purposive 
sampling (RR n/a) 
key issues highlighted include 
inconsistent definitions of IFs, 
when and how to inform 
patients, minimising 
psychological harm, and 
having flexible disclosure 
guidelines 
how certain the significance of 
the IF is; possible psychological 
harm (anxiety, turmoil); 
patients' difficulty in 
understanding the IF 
Driessnack, 
Daack-Hirsch, 
Downing, 
Hanish, Shah, 
Alasagheirin, 
Simon, 
Williams 
(2013) 
USA; paediatric 
genomic 
research and 
clinical practice 
broad cross-
section of 
professional 
and public 
stakeholders in 
paediatric 
genomic 
research and 
clinical practice 
to capture the 
unique issues and 
challenges 
surrounding the 
discovery and 
disclosure of 
incidental genomic 
findings when 
children are involved 
qualitative - 
interviews and focus 
groups 
103 professionals, 
63 members of the 
public, obtained 
through purposeful, 
stratified sampling 
(RR n/a) 
one overarching theme: "it's 
hard for us; it's hard for them"; 
distinctions separating 
professionals from lay groups 
clustered around three 
subquestions: what to 
disclose, who gets the 
information, and what 
happens later? 
professionals: the complex 
nature of interpreting IFs eg the 
accuracy in predicting 
associated phenotypes; easier 
decision when the IF is clear and 
life-threatening or actionable, 
more difficult if untreatable or 
adult-onset; complex family 
dynamics and growing maturity 
of the child relevant in 
communication; consider 
carefully the possible impact on 
the child of disclosure, including 
for their later reproductive 
choices. Lay groups: ambiguity 
is a fact of life, so not repelled 
by the ambiguity of IFs; desire 
to receive information so as to 
be prepared; parents should 
decide if, when and how IFs are 
shared with their children 
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Green, Berg, 
Berry, 
Biesecker, 
Dimmock, 
Evans, Grody, 
Hegde, Kalia, 
Korf, Krantz, 
McGuire, 
Miller, Murray, 
Nussbaum, 
Plon, Rehm, 
Jacob (2012) 
USA; clinical 
genetics 
clinical 
geneticists 
and/or 
molecular 
medicine 
specialists 
to explore specific 
conditions and types 
of genetic variants 
that specialists in 
genetics recommend 
should be returned 
as IFs in clinical 
sequencing quantitative - survey 16; RR not reported 
considerable concordance on 
what to return (80% 
agreement for 65% of the 
conditions), discordance on 
what factors influence 
decision-making; a small panel 
of experts will not be able to 
agree on what to return 
treatability or prevention 
possibilities; quality of the 
finding; presence of a minor 
Haga, O'Daniel, 
Tindall, Lipkus, 
Agans (2011) 
USA; clinical 
pharmaco-
genetic testing public 
to explore public 
attitudes regarding 
pharmacogenetic 
(PGx) testing and the 
role ancillary 
information might 
play in decisions to 
undergo such tests 
quantitative - 
explorative, 
random-digit-dial 
telephone survey n=1 139 (RR=42%) 
the potential of ancillary 
information does not 
negatively impact public 
interest in PGx testing, 
possibly even the opposite; 
interest in learning ancillary 
information is well-aligned 
with the public's desire to be 
informed about potential 
benefits and risks prior to 
testing 
interest of potential recipients 
in incidental findings; 
seriousness and treatability of 
the finding; disease context 
Haga, Tindall, 
O'Daniel 
(2012a) 
USA; clinical 
pharmaco-
genetic testing 
health care 
professionals 
(primary care 
professionals 
[PCPs] and 
geneticists) 
to assess health care 
professionals' 
attitudes on 
pharmacogenetic 
(PGx) testing, 
ancillary disease risk 
information and 
related clinical issues 
qualitative - focus 
groups with 
questions and a 
hypothetical 
vignette 
21 health care 
professionals, 3 
focus groups 
positive interest in PGx testing, 
though less for PCPs because 
of various concerns; many 
PCPs feel an obligation to 
disclose, geneticists not 
because of the complexity of 
results. Authors recommend 
more educational resources, 
access to genetic specialists, 
and clear clinical guidelines 
about the use of PGx testing 
potential psychological risks 
(fear); duty to disclose; 
communication challenges 
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Haga, Tindall, 
O'Daniel 
(2012b) 
USA; clinical 
pharmaco-
genetic testing 
general public 
from Durham, 
NC 
to gain a better 
understanding of the 
views of the general 
public on 
pharmacogenetic 
(PGx) testing, 
ancillary disease risk 
information and 
related clinical issues 
qualitative - focus 
groups with 
questions and a 
hypothetical 
vignette 
45 individuals, 4 
focus groups 
enthusiastic about PGx testing; 
most participants agreed that 
doctors are obliged to disclose 
ancillary risk information, 
though some were then 
hesitant about actually 
learning it; concerns of privacy, 
confidentiality, and 
psychological harms from 
ancillary information; 
implications for physicians 
duty to disclose; actionability of 
the finding; possible harms 
(anxiety, psychological harm, 
insurance discrimination); 
question of who discloses 
Hayeems, 
Miller, Li, 
Bytautas 
(2011) 
Canada/inter-
national; 
genetic 
research 
cystic fibrosis 
and autism 
genetic 
researchers 
to better understand 
a range of factors 
that might influence 
how researchers 
establish clinical 
significance and 
reportability 
quantitative - quasi-
experimental; 
international cross-
sectional survey 
2187 possible 
authors, 877 
eligible 
participants, 785 
eligible surveys, RR 
44% 
80% agree in principle that 
clinically significant findings be 
disclosed, but specific 
judgements varied based on 
scientific factors, capacity of 
the team to explain the 
results, and type of research 
ethics guidance; the type of 
researcher, their primary role 
and their beliefs about a 
general reporting obligation 
also had an impact; results call 
into question the assumption 
that everyone will return the 
same results 
replication, robustness, and 
intentionality of the finding; 
extent of the information; 
specificity of the informed 
consent; clinical utility; disease 
context; consultation of 
colleagues and IRB 
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Lemke, Bick, 
Dimmock, 
Simpson, Veith 
(2012) 
USA; clinical 
genetics 
clinical genetics 
professionals 
to investigate the 
views of clinical 
genetics 
professionals on 
WGS and IFs when it 
involves themselves, 
their children, and 
adults and children 
in a clinical care 
setting quantitative - survey 
279 clinical genetics 
professionals; 
approximately 90% 
uptake rate 
participants' views were 
strongly dependent on clinical 
actionability and the presence 
of a minor: the vast majority 
agreed that they were 
interested in knowing about 
clinically actionable IFs in 
themselves (96%) and their 
child (99%), and that these 
types of IFs should be 
disclosed in adult (96%) and 
minor (98%) patients; 
percentages dropped to 
around 70% for an adult-onset 
clinically actionable disease 
and a childhood-onset, non-
clinically actionable disease, 
and dropped even further for 
an adult-onset non-clinically 
actionable condition 
clinical actionability of the IF; 
presence of a minor 
Lohn, Adam, 
Birch, 
Townsend, 
Friedman 
(2013) 
Canada; clinical 
whole genome 
sequencing 
(WGS) 
geneticists and 
genetic 
counsellors 
to investigate the 
views of geneticists 
and genetic 
counsellors in 
Canada on the 
disclosure of IFs 
arising from clinical 
sequencing 
investigations 
quantitative - online 
questionnaire 
210 clinical genetics 
professionals; RR 
42% 
geneticists and genetic 
counsellors largely in 
agreement that actionable IFs 
should be readily disclosed to 
patients while other IFs should 
not be readily disclosed; pre-
test informed consent process 
emphasised 
nature of the finding (ranging 
from a serious and treatable 
condition to an IF with social 
implications eg non-paternity); 
presence of a minor; test 
accuracy; evidence indicating 
pathogenicity; what was agreed 
upon if there was a pre-test 
counselling session 
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Matsui, Lie, 
Kita, Ueshima 
(2008) 
Japan; genetic 
research 
research 
participants 
to investigate the 
actual preferences 
of donors [of genetic 
samples] with regard 
to receiving 
individual results; to 
explore the factors 
related to their 
decision 
quantitative - 
prospective 
population-based 
genetic 
epidemiologic 
study; two item 
questionnaire 
1845 (99.4%) for 
question 1, 1767 
(95.2%) for 
question 2, 1758 
(94.7%) answered 
both questions 
most participants want to be 
recontacted and want reports 
of IFs; some sociodemographic 
associations 
interest of potential recipients 
in incidental findings; disease 
context 
Meacham, 
Starks, Burke, 
Edwards 
(2010) 
USA; genetic 
research researchers 
to better understand 
researchers' 
problem-solving 
strategies, reasoning 
processes, and 
motivations for 
dealing with the 
challenge of IFs 
qualitative - semi-
structured 
telephone 
interviews, with 5 
hypothetical 
vignettes 
60 researchers from 
Washington State 
and Oregon, of a 
possible 125 
(RR=48%); 44 
responded to the 
return of 
unexpected results 
vignette 
primary question is how to 
disclose, related to 3 
potentially conflicting duties: 
information quality, 
participant welfare, adherence 
to rules. Also important: 
involving others and practical 
considerations 
clinical utility; quality and 
replication of the finding; 
maximise benefits and minimise 
harms (reasons for and against 
disclosure) and the support and 
resources necessary to do this; 
duties of researchers; 
communication issues; right to 
know 
Ries, 
LeGrandeur, 
Caulfield 
(2010) 
Europe/North 
America 
(Canada, 
Denmark, 
England, 
France, the 
Netherlands, 
USA); genetic 
research - birth 
cohort studies 
investigators 
involved in 6 
birth cohort 
studies 
to examine how a 
sample of birth 
cohort studies in 
North America and 
Europe has handled 
certain key ELS 
issues (recruitment, 
nature of consent 
sought, 
confidentiality and 
sample/data 
protection 
measures, handling 
sensitive 
information, 
disclosure of results, 
withdrawal) 
qualitative - semi-
structured 
telephone 
interviews 
lead investigators 
from 6 birth cohort 
studies, out of a 
possible 14 
contacted 
(RR=43%) 
not all studies tell participants 
about how sensitive 
information will be handled; 
studies vary on whether 
results of more routine tests 
and measures will be returned, 
nothing of unknown clinical 
significance returned 
possibility of disclosure; clinical 
utility; scientific validity; 
actionability 
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Simon, 
Williams, 
Shinkunas, 
Brandt, Daack-
Hirsch, 
Driessnack 
(2011) 
USA; research 
genome-wide 
association 
studies (GWAS) 
institutional 
review board 
(IRB) chairs at 
centres 
conducting 
GWAS 
an exploratory 
descriptive study to 
gain a preliminary 
understanding of 
emerging IRB 
perspectives and 
practices in relation 
to addressing 
genomic incidental 
findings (GIFs) in 
informed consent 
processes 
qualitative - semi-
structured 
interviews 
34 chairs; RR n/a 
("purposive 
sample" and 
interviews 
continued until 
saturation was 
reached) 
most chairs reported no 
knowledge of local IRB 
requirements regarding GIFs 
and informed consent, though 
several had experience with 
IFs; several suggestions made 
about how to improve consent 
processes; concerns regarding 
participant disclosure 
preferences changing over 
time, inherent limitations in 
determining the scope and 
accuracy of claims about GIFs, 
and making consent processes 
longer and more complex 
the autonomy of research 
participants and their right to 
change their mind regarding 
disclosure preferences should 
be respected in the informed 
consent process 
Townsend, 
Adam, Birch, 
Lohn, 
Rousseau, 
Friedman 
(2012) 
Canada; clinical 
whole genome 
sequencing 
(WGS) 
genetics health-
care 
professionals, 
the general 
public, and 
parents whose 
children have 
experienced 
genetic testing 
to explore and 
compare practical 
and ethical issues 
concerning 
disclosure of IFs in 
clinical settings from 
the perspective of 
some stakeholders 
qualitative - focus 
groups 
10 genetics health 
care professionals 
(RR=10/24); 8 
parents 
(RR=8/(25*2?)); 10 
lay people (RR n/a) 
5 dominant themes emerged: 
pre-test discussions 
(important, but disagreement 
on whether IFs could be 
categorised or not), patient 
choice, patient responsibility 
(for following up future 
developments, because of 
limited clinical resources), 
communicating IFs (with 
sensitivity and 
comprehensively), impact and 
implications of IFs (anxiety, 
discrimination, wider family) 
pre-test discussion and other 
communication issues; clinical 
relevance including seriousness, 
urgency, treatability, 
probability; also clinical 
relevance from the patient's 
viewpoint; justice; property and 
ownership, also in terms of the 
broader family; respect for 
autonomous choice; minimise 
potential harms (confusion, 
anxiety, possible 
discrimination); responsibilities 
of health care professionals and 
patients; presence of a minor 
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Williams, 
Daack-Hirsch, 
Driessnack, 
Downing, 
Shinkunas, 
Brandt, Simon 
(2012) 
USA; research 
genome-wide 
association 
studies (GWAS) 
genomic 
researchers and 
institutional 
review board 
(IRB) chairs at 
centres 
conducting 
GWAS 
to examine 
researcher and IRB 
chair perspectives 
on genomic 
incidental findings 
(GIFs) 
qualitative - semi-
structured 
telephone 
interviews 
19 genomic 
researchers and 34 
IRB chairs from 42 
institutions;  RR n/a 
("purposive 
sample" and 
interviews 
continued until 
saturation was 
reached) 
researchers favoured policies 
offering a case-by-case 
determination of GIF 
disclosure after discovery; IRB 
chairs favoured policies 
determining procedures for 
GIF disclosure prior to 
approval of the research 
researchers: generally not in 
favour of disclosure as not 
coinciding with the purpose of 
research, to generate 
knowledge; GIFs with clear or 
probable medical significance 
should be disclosed, while GIFs 
of uncertain significance were 
seen as a difficult issue. IRB 
chairs: beneficence and 
minimising harm could be 
reasons to override a stated 
desire (not) to know 
 414 
 415 
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